1. Home
  2. KITT vs APRE Comparison

KITT vs APRE Comparison

Compare KITT & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nauticus Robotics Inc.

KITT

Nauticus Robotics Inc.

HOLD

Current Price

$2.31

Market Cap

11.8M

Sector

Industrials

ML Signal

HOLD

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.81

Market Cap

10.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KITT
APRE
Founded
2014
2006
Country
United States
United States
Employees
47
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.8M
10.6M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
KITT
APRE
Price
$2.31
$0.81
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.10
AVG Volume (30 Days)
1.4M
342.8K
Earning Date
04-16-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.22
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.39
$0.55
52 Week High
$6.93
$2.22

Technical Indicators

Market Signals
Indicator
KITT
APRE
Relative Strength Index (RSI) 65.96 47.13
Support Level $0.67 $0.57
Resistance Level $3.54 $0.98
Average True Range (ATR) 0.23 0.11
MACD 0.19 -0.01
Stochastic Oscillator 62.12 19.67

Price Performance

Historical Comparison
KITT
APRE

About KITT Nauticus Robotics Inc.

Nauticus Robotics Inc develops fully electric autonomous robotic solutions for subsea applications. The company's business model includes using robotic systems for service, selling vehicles and components, and licensing related software to both the commercial and defense business sectors. The company's addressable markets include upstream, midstream, and downstream oil and gas, defense, offshore renewables, seafloor telecommunications, aquaculture, port security, oceanographic research, and subsea mining.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: